Overview Technology transfer process Services Business development Marketing Patents Legal Yissum staff Researcher Area Overview Strategies Team Directors Products Companies News Events Press Releases Newsletters Picture Gallery BioMed 2009 Exhibitions Biomed 2010 Movies Computer Science Subsidiaries Yissum Press Releases 47 records page 1-3 07/09/2010 Hebrew U. goes global – thanks to accredited online courses with eTeacher The lessons are conducted in small groups via the online study site of the company, eTeacher, which recently signed an agreement of cooperation with Yissum, the technology transfer company of the Hebrew University. Read More... 17/06/2010 Potato Power - Yissum Introduces Potato Batteries for Use in the Developing World Yissum introduces solid organic electric battery based upon treated potatoes. This simple, sustainable, robust device can potentially provide an immediate inexpensive solution to electricity needs in parts of the world lacking electrical infrastructure. Read More... 25/05/2010 A Pill in a Haystack - Yissum Introduces a Breakthrough Computational Method for Superfast Drug Discovery Yissum introduces Dralgo, a novel computational platform for accelerated discovery of promising drug candidates. The new technology will be presented by Professor Amiram Goldblum from the Hebrew University on Tuesday, June 15 at the Technology Transfer Session II of the ILSI Biomed Israel 2010 conference, to be held at the David Intercontinental Hotel, Tel Aviv, Israel. Read More... 21/04/2010 Yissum Licenses Cutting Edge Technology for Enhanced Digital Image Processing to Adobe Systems The technology, invented by Dr. Raanan Fattal from the Hebrew University's School of Computer Science and Engineering, is called Edge Avoiding Wavelets and it enables better and faster detail enhancement and preserves edges when sharpening digital images. Read More... 14/04/2010 Yissum, Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease Yissum has also announced that, together with the Technion Research and Development Foundation (TRDF), the technology transfer arm of the Technion Israel Institute of Technology, it will exclusively license to Avraham the commercial rights of Ladostigil, a novel cholinesterase, brain-selective monoamine oxidase inhibitor and neuroprotective agent for treatment of Alzheimer's disease and other neurodegenerative diseases. Read More... 18/02/2010 Yissum Introduces a Novel System for Tracking and Analyzing Human Spatial Behavior by Monitoring People's Mobility for Tourism, Town Planning and Healthcare Applications The novel system monitors people's movements and use of open space to provide accurate data for use in healthcare, urban planning, retail yield management, law enforcement and tourism management. The technology was developed by Dr. Noam Shoval and Michal Isaacson, of the Hebrew University’s Department of Geography. Read More... 03/02/2010 Yissum to Collaborate with Makhteshim Agan on the Development and Commercialization of Two Environmentally-Friendly Crop Protection Technologies The first collaboration is for the development and commercialization of a novel methodology for producing slow and controlled release of herbicides. The innovative technique will minimize herbicide contamination of soil and water. It was invented by Prof. Shlomo Nir and Dr. Yael Mishael from the Department of Soil and Water Sciences, and by Prof. Baruch Rubin, from the Robert H. Institute of Plant Science and Genetics in Agriculture, all from the Hebrew University’s Robert H. Smith Faculty of Agriculture, Food and Environment. Read More... 14/12/2009 Yissum Presents a New Antiviral Hand Sanitizer that Completely Inactivates the Swine Flu Virus Yissum presents EtoCleanTM, a new antiviral hand sanitizer which has been found to be highly effective against the swine flu virus. The novel product was invented by Professor Elka Touitou from the School of Pharmacy, at the Hebrew University of Jerusalem and is being developed by Novel Therapeutic Technologies (NTT), a spin-off company of Yissum. Read More... 25/11/2009 Yissum Introduces a Novel Method for Ranking Online Reviews This novel method for content analysis, invented by Professor Ari Rappoport and Mr. Oren Tsur from the Hebrew University School of Computer Science and Engineering, is specifically designed to automatically rank book and product reviews according to their estimated helpfulness. Read More... 11/11/2009 Yissum Introduces a Novel, Environmentally-Friendly Method for Preventing and Affecting Biofilm of Bacteria and Fungi The invention, developed by HUJI Professors Doron Steinberg and Morris Srebnik, together with Professor Itzhack Polacheck from the Hadassah Medical Organization, utilizes novel heterocyclic compounds that disrupt cell-cell communication, thereby interfering with the formation of biofilms. Read More... 02/11/2009 Yissum and BrightSource Industries Israel Sign Research Agreements for the Development of New Materials for Solar Power Plants Under the agreement, BrightSource will fund research in the laboratories of Professors Daniel Mandler, and Shlomo Magdassi, both from the Institute of Chemistry at the Hebrew University of Jerusalem. Read More... 22/10/2009 Yissum Announces Long-Term Multi-Project Research and License Collaboration with Roche According to the terms of the agreement, Roche has selected six promising research projects in the fields of stem cells, biomarkers, and novel molecules for the treatment of metabolic diseases, initiated by Hebrew University researchers. Read More... 19/10/2009 Yissum Introduces Novel Nanotechnology for Revolutionizing Imaging Using T-rays The novel device will have 400 times higher gain than THz quantum cascade lasers, the only coherent T-ray sources existing today. This invention will make T-ray based cameras and spectrometers practical, ushering a new era in security and medical imaging. Read More... 14/07/2009 Yissum Licenses Stem Cell Technologies for Spinal Therapy to TheraCell, Inc. Yissum announced that it has licensed a novel package of stem cell related technologies to TheraCell, Inc., which will further develop and commercialize the technology for advanced regenerative medicine procedures such as spinal fusion. The technology was invented by a team headed by Professor Dan Gazit from the Faculty of Dental Medicine. Read More... 24/06/2009 Yissum Spin-off Atox Bio and Fast-Track Drugs & Biologics Sign an R&D Collaboration Agreement for the Development of Therapeutics for Sepsis and Septic Shock The collaboration is funded by the Israel-U.S. binational BIRD Foundation Read More... 15/06/2009 Yissum Signs a Collaboration Agreement with Aurum Ventures MKI for the Development of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology The technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy. Read More... 09/06/2009 Yissum Introduces Novel Compound for the Treatment of Osteoporosis Professor Itai Bab and Professor Raphael Mechoulam, from the School of Pharmacy at the Hebrew University of Jerusalem, invented a new drug candidate for the treatment of osteoporosis that both inhibits bone resorption and stimulates bone formation. Read More... 25/05/2009 Z-Cube and Yissum sign a Licensing Agreement for the Development of an Innovative Nanotechnology Drug Delivery System for the Treatment of Pain Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for pain applications and will sponsor a research program to be conducted by Professor Elka Touitou from the Hebrew University's Faculty of Medicine. Read More... 06/04/2009 Yissum Appoints Yaacov Michlin as Chief Executive Officer Yissum announced today the appointment of Yaacov Michlin as Chief Executive Officer, effective May 1, 2009. The Company also announced that Yehuda Yarmut, who until recently was Executive Vice President Licensing & IP, was promoted and appointed Deputy Chief Executive Officer. Read More... 30/03/2009 Merck KGaA and Yissum Sign R&D Collaboration Agreement Merck to sponsor three-year joint R&D program with Yissum's spin-off, QLight Nanotech, for the development of novel semiconductor nanoparticles technology for optical applications Read More... 1 2 3 |  NEXT     Advanced News Events Press Releases Newsletters Picture Gallery Movies
	All rights reserved to Yissum    |    disclaimer ICS בניית אתרים